Abstract

Epidemiologic and laboratory studies indicate that dietary selenium protects against prostate cancer. Results from clinical trials suggest that selenium-enriched yeast (SY) but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk. Our objectives were to directly compare for the first time the effects of SeMet and SY on prostate cancer relevant biomarkers in men. We performed a randomized double blind, placebo-controlled trial of SY (200 or 285 μg/day) and SeMet (200 μg/day) administered for 9 months in 69 healthy men. Primary endpoints included blood levels of selenium-containing compounds and oxidative stress biomarkers [urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-iso-prostaglandin-F (8-iso-PGF) and blood glutathione (GSH)]. Secondary endpoints included plasma glucose and PSA levels. Compliance was high in all groups (>95%). Plasma selenium levels were increased 93%, 54%, and 86% after 9 months in SeMet and low- and high-dose SY groups, respectively, and returned to baseline levels after a 3-month washout (P < 0.05). Levels of 8-OHdG and 8-iso-PGF were decreased 34% and 28%, respectively, after 9 months in the high-dose SY group ( P < 0.05). These decreases were greatest in individuals with low baseline plasma levels of selenium (<127 ng/mL). No changes in serum PSA or blood glucose and GSH were observed. Overall, we showed for the first time, reductions in biomarkers of oxidative stress following supplementation with SY but not SeMet in healthy men. These findings suggest that selenium-containing compounds other than SeMet may account for the decrease in oxidative stress.

Original languageEnglish (US)
Pages (from-to)796-804
Number of pages9
JournalCancer Prevention Research
Volume7
Issue number8
DOIs
StatePublished - Jan 1 2014

Fingerprint

Selenium
Selenomethionine
Oxidative Stress
Randomized Controlled Trials
Biomarkers
Yeasts
Selenium Compounds
Prostatic Neoplasms
Prostaglandins F
Tumor Biomarkers
Compliance
Glutathione
Blood Glucose
Epidemiologic Studies
Placebos
Clinical Trials
Urine
Glucose
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{4f5a1f682dfe416d83260686569d2370,
title = "Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: A randomized clinical trial",
abstract = "Epidemiologic and laboratory studies indicate that dietary selenium protects against prostate cancer. Results from clinical trials suggest that selenium-enriched yeast (SY) but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk. Our objectives were to directly compare for the first time the effects of SeMet and SY on prostate cancer relevant biomarkers in men. We performed a randomized double blind, placebo-controlled trial of SY (200 or 285 μg/day) and SeMet (200 μg/day) administered for 9 months in 69 healthy men. Primary endpoints included blood levels of selenium-containing compounds and oxidative stress biomarkers [urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-iso-prostaglandin-F 2α (8-iso-PGF2α) and blood glutathione (GSH)]. Secondary endpoints included plasma glucose and PSA levels. Compliance was high in all groups (>95{\%}). Plasma selenium levels were increased 93{\%}, 54{\%}, and 86{\%} after 9 months in SeMet and low- and high-dose SY groups, respectively, and returned to baseline levels after a 3-month washout (P < 0.05). Levels of 8-OHdG and 8-iso-PGF2α were decreased 34{\%} and 28{\%}, respectively, after 9 months in the high-dose SY group ( P < 0.05). These decreases were greatest in individuals with low baseline plasma levels of selenium (<127 ng/mL). No changes in serum PSA or blood glucose and GSH were observed. Overall, we showed for the first time, reductions in biomarkers of oxidative stress following supplementation with SY but not SeMet in healthy men. These findings suggest that selenium-containing compounds other than SeMet may account for the decrease in oxidative stress.",
author = "John Richie and Arunangshu Das and Calcagnotto, {Ana M.} and Raghu Sinha and Wanda Neidig and Liao, {Jiangang (Jason)} and Eugene Lengerich and Arthur Berg and Hartman, {Terryl Johnson} and Amy Ciccarella and Aaron Baker and Kaag, {Matthew G.} and Susan Goodin and DiPaola, {Robert S.} and Karam El-Bayoumy",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/1940-6207.CAPR-14-0042",
language = "English (US)",
volume = "7",
pages = "796--804",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men : A randomized clinical trial. / Richie, John; Das, Arunangshu; Calcagnotto, Ana M.; Sinha, Raghu; Neidig, Wanda; Liao, Jiangang (Jason); Lengerich, Eugene; Berg, Arthur; Hartman, Terryl Johnson; Ciccarella, Amy; Baker, Aaron; Kaag, Matthew G.; Goodin, Susan; DiPaola, Robert S.; El-Bayoumy, Karam.

In: Cancer Prevention Research, Vol. 7, No. 8, 01.01.2014, p. 796-804.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men

T2 - A randomized clinical trial

AU - Richie, John

AU - Das, Arunangshu

AU - Calcagnotto, Ana M.

AU - Sinha, Raghu

AU - Neidig, Wanda

AU - Liao, Jiangang (Jason)

AU - Lengerich, Eugene

AU - Berg, Arthur

AU - Hartman, Terryl Johnson

AU - Ciccarella, Amy

AU - Baker, Aaron

AU - Kaag, Matthew G.

AU - Goodin, Susan

AU - DiPaola, Robert S.

AU - El-Bayoumy, Karam

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Epidemiologic and laboratory studies indicate that dietary selenium protects against prostate cancer. Results from clinical trials suggest that selenium-enriched yeast (SY) but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk. Our objectives were to directly compare for the first time the effects of SeMet and SY on prostate cancer relevant biomarkers in men. We performed a randomized double blind, placebo-controlled trial of SY (200 or 285 μg/day) and SeMet (200 μg/day) administered for 9 months in 69 healthy men. Primary endpoints included blood levels of selenium-containing compounds and oxidative stress biomarkers [urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-iso-prostaglandin-F 2α (8-iso-PGF2α) and blood glutathione (GSH)]. Secondary endpoints included plasma glucose and PSA levels. Compliance was high in all groups (>95%). Plasma selenium levels were increased 93%, 54%, and 86% after 9 months in SeMet and low- and high-dose SY groups, respectively, and returned to baseline levels after a 3-month washout (P < 0.05). Levels of 8-OHdG and 8-iso-PGF2α were decreased 34% and 28%, respectively, after 9 months in the high-dose SY group ( P < 0.05). These decreases were greatest in individuals with low baseline plasma levels of selenium (<127 ng/mL). No changes in serum PSA or blood glucose and GSH were observed. Overall, we showed for the first time, reductions in biomarkers of oxidative stress following supplementation with SY but not SeMet in healthy men. These findings suggest that selenium-containing compounds other than SeMet may account for the decrease in oxidative stress.

AB - Epidemiologic and laboratory studies indicate that dietary selenium protects against prostate cancer. Results from clinical trials suggest that selenium-enriched yeast (SY) but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk. Our objectives were to directly compare for the first time the effects of SeMet and SY on prostate cancer relevant biomarkers in men. We performed a randomized double blind, placebo-controlled trial of SY (200 or 285 μg/day) and SeMet (200 μg/day) administered for 9 months in 69 healthy men. Primary endpoints included blood levels of selenium-containing compounds and oxidative stress biomarkers [urine 8-hydroxy-2′-deoxyguanosine (8-OHdG) and 8-iso-prostaglandin-F 2α (8-iso-PGF2α) and blood glutathione (GSH)]. Secondary endpoints included plasma glucose and PSA levels. Compliance was high in all groups (>95%). Plasma selenium levels were increased 93%, 54%, and 86% after 9 months in SeMet and low- and high-dose SY groups, respectively, and returned to baseline levels after a 3-month washout (P < 0.05). Levels of 8-OHdG and 8-iso-PGF2α were decreased 34% and 28%, respectively, after 9 months in the high-dose SY group ( P < 0.05). These decreases were greatest in individuals with low baseline plasma levels of selenium (<127 ng/mL). No changes in serum PSA or blood glucose and GSH were observed. Overall, we showed for the first time, reductions in biomarkers of oxidative stress following supplementation with SY but not SeMet in healthy men. These findings suggest that selenium-containing compounds other than SeMet may account for the decrease in oxidative stress.

UR - http://www.scopus.com/inward/record.url?scp=84905828095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905828095&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-14-0042

DO - 10.1158/1940-6207.CAPR-14-0042

M3 - Article

VL - 7

SP - 796

EP - 804

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 8

ER -